ORIC Pharmaceuticals, Inc. — Form 8-K Summary
Business context and reporting period
ORIC Pharmaceuticals, Inc. filed a Form 8-K on May 6, 2024, under Items 2.02 and 9.01. The filing announces the release of financial results for the fiscal quarter ended March 31, 2024. ORIC is a Delaware corporation headquartered in South San Francisco, California, and its common stock trades on the Nasdaq Global Select Market under the symbol ORIC.
Financial metrics
The filing references a press release containing the quarterly financial results, filed as Exhibit 99.1, but the provided filing text does not include the press release content or clear values for revenue, net loss, cash flow, cash and investments, margins, debt, liquidity, or other financial metrics.
Material changes versus the prior comparable period
The provided filing text does not describe changes versus the prior-year comparable quarter or provide comparative financial data.
Guidance, outlook, risks, and unusual items
The filing itself does not provide guidance, management outlook, risk updates, contingencies, or unusual-item commentary. It only furnishes the quarterly-results press release by reference.
The information furnished under Items 2.02 and 9.01, including Exhibit 99.1, is not deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor verification points
- Review Exhibit 99.1 for the actual quarterly financial results and comparative figures.
- Verify reported cash, cash equivalents, investments, operating cash burn, and expected liquidity runway.
- Check for any updated clinical-development milestones, pipeline commentary, guidance, or risk disclosures in the press release.
- Confirm whether the company reported any debt, financing activity, collaboration revenue, or other unusual items for the quarter.